search:nccn guideline cervical cancer相關網頁資料
nccn guideline cervical cancer的相關文章
nccn guideline cervical cancer的相關公司資訊
nccn guideline cervical cancer的相關商品
瀏覽:1253
日期:2024-12-22
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) are posted
with the latest update date and version number. The NCCN Guidelines are ......
瀏覽:1387
日期:2024-12-20
NCCN Guidelines are widely recognized and used as the standard for ... tests
and cancer precursors: 2012 updated consensus guidelines for the management
......
瀏覽:1337
日期:2024-12-24
Version 2.2013, 10/25/12 © National Comprehensive Cancer Network, Inc. 2012, All rights reserved. The NCCN Guidelines and this illustration may not be reproduced in any form without the express written permission of NCCN®.® NCCN Guidelines Index Cervical ...
The NCCN Clinical Practice Guidelines on Venous Thromboembolic Disease: Strategies for Improving VTE
瀏覽:636
日期:2024-12-17
The Oncologist is a journal devoted to medical and practice issues for surgical, radiation, and medical oncologists. ... I ntroduction Studies have long reported the association between cancer and venous thromboembolism (VTE), which comprises both deep .....
瀏覽:354
日期:2024-12-19
Cervical Cancer Screening Guideline 5 Women 21 Years and Older: Management of Pap Results Pap results There are two screening options at Group Health: Pap test every 3 years for women over 21 years of age (preferred option), and Pap test and HPV co ......
瀏覽:1179
日期:2024-12-18
Version 2.2010, 08/17/09 © 2009 National Comprehensive Cancer Network, Inc. All rights reserved. These guidelines and this illustration may not be reproduced in any form without the express written permission of NCCN. Practice Guidelines in Oncology – v.2...
瀏覽:1144
日期:2024-12-22
Peer Reviewed Publications: Al-Shakhrah IA. Radioprotection using iodine-131 for thyroid cancer and hyperthyroidism: a review. Clin J Oncol Nurs. 2008; 12(6):905-912. Brooks SE, Chen TT, Ghosh A, et al. Cervical cancer outcomes analysis: impact of age, ra...
瀏覽:1096
日期:2024-12-18
Results from the phase III GOG 240 trial, presented at ASCO, showed the addition of bevacizumab (Avastin) to standard chemotherapy improved overall survival by nearly 4 months in women with advanced or relapsed cervical cancer....